[Oncogenesis] Scientists elucidated that BCL-xL is the major pro-survival protein in prostate cancer cell lines after docetaxel treatment, which can be reverted using BH3 mimetics or PROTAC strategies against this protein.
Dual Downregulation of HRK and BAD Promotes BCL-Xl-Mediated Docetaxel Resistance in Prostate Cancer
Emily Salmini


